MedTrace Logo

Treatment of Hypertension

NCT00000484 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2013-11-26

No results posted yet for this study

Summary

To determine whether the long-term treatment of essential hypertension without significant target organ disease materially influenced mortality and/or cardiovascular renal morbidity.

Conditions

Interventions

DRUG

chlorothiazide

DRUG

Rauwolfia alkaloids

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    lead NIH

Principal Investigators

  • Anthony Damato · USPHS Hospital

  • Richard Thurm · USPHS Hospital

  • Christfried Urner · USPHS Hospital

  • John Vaillancourt · USPHS Hospital

  • J. Warbasse · USPHS Hospital

  • Robert Wells · USPHS Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1966-04-30
Completion
1979-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000484 on ClinicalTrials.gov